1. Revised objectives and other text to expand the definition of overall success to include resolution of systemic signs and symptoms attributable to candidemia, and to evaluate mycological success and clinical cure at additional time points. 2. Added endpoint of overall response. Overall response will be determined programmatically from the mycological response and assessment of clinical signs and symptoms attributable to candidemia, along with definitions of success, failure, and indeterminate. 3. Revised definitions of clinical responses of Cure and Failure for clarity. 4. Clarified timing of blood sample collection for PK analysis. 5. Redefined mITT Population to use a central laboratory evaluation of blood culture. 6. Revised to allow IVD use for mycological diagnosis for enrollment. 7. Revised sample size from 90 to approximately 114 to allow use of IVD (some subjects may be enrolled without positive blood cultures). 8. Clarified exclusion criteria regarding the use of the Child-Pugh score and the timing of the use of other investigational drugs. 9. Added dose adjustments for weight and creatinine clearance. 10. Clarified windows for various evaluations and procedures. 11. Specified that the PI is to assess clinical response. 12. Changed FU Visit from Days 28-35 to Days 45-52. 13. Required additional blood culture closer to randomization. 14. Changed from APACHE II score to modified APACHE II score.

Italian Specific Amendment. Added justification for use of rezafungin in candidemia treatment.

1. Removed assessment of subject symptoms and provided further examples of signs of infection. 2. Clarified consideration of subjects with endophthalmitis or indwelling catheters. 3. Added lyophilized formulation of rezafungin, Rezafungin for Injection, and directions for use. Sites will transition from the liquid formulation (CD101 Injection) to the lyophilized formulation (CD101 for Injection). Each subject will receive only one CD101 formulation. Subjects starting on the liquid CD101 will remain on that formulation. 4. Defined stricter criteria for switching to oral therapy and provided safety information on oral fluconazole. 5. Clarified blood collection and processing for PK analysis. 6. Clarified what sites should consider regarding selection of alternative therapy after discontinuation of study treatment.

German specific amendment. 1. Deleted LAR authority. 2. Clarified consideration of subjects with endophthalmitis or indwelling catheters, and consideration of step-down therapy. 3. Clarified what sites should consider regarding selection of alternative therapy.

1. Added eligibility of subjects with IC, added treatment, time points, assessments, and descriptions unique to that population. 2. Increased planned study centers to approximately 60 (from approximately 45). 3. Clarified that the Day 15 study drug infusion was optional for all subjects and the Day 22 infusion was an option only for subjects with IC. 4. Added text regarding collecting blood or normally sterile tissue or fluid for culture. 5. Added radiologic tests. 6. Expanded definition of mycological eradication to include normally sterile sites other than blood and definition of presumed mycological eradication. 7. Specified that safety data collection starts when the IC is signed and continues through the FU Visit. 8. Clarified that PK data will be reported separately for the PK Analysis Population.

Clarified that the FU Visit for all subjects with IC is on Days 52-59.

1. Added Part B to the study to increase the study sample size; defined procedures, assessments, and analysis. “After approximately 90 subjects have been enrolled in the mITT Population in Part A, enrollment into Part A of the study will close and Part B will begin. In Part B, subjects will be randomized in a 2:1 ratio to receive rezafungin treatment group 1 or IV caspofungin until ≥45 additional subjects and no more than 120 subjects have been enrolled. Total enrollment will depend on the enrollment rate for the 6- to 8-month period between the end of Part A and the start of the Phase 3 study, which is the trigger for Part B to stop enrollment. Oral step-down therapy is allowed in both treatment groups in Part B; oral placebo in the rezafungin group and oral fluconazole in the caspofungin group.” 2. Defined that for Part B only, subjects with a positive T2Candida Panel without a positive Candida culture were presumed to have IC. 3. Clarified criteria for oral step-down therapy in Part B for subjects without a positive blood culture but with a positive T2Candida Panel at Screening. 4. Added stopping criteria for IC and T2Candida positive (blood culture negative) subjects. 5. Defined interim analysis procedures for Part A data after Part A database lock. 6. Added that samples will not be collected for PK analysis in Part B. 7. Clarified that only subjects with candidemia require a retinal examination. 8. Changed (from 4 and 8 hours after the start of the infusion to between 15 minutes and 1 hours after the end of the infusion) and added blood collection timepoints (between 2 and 12 hours after the end of the infusion) for samples for PK analysis, clarified PK sample processing procedure.

1. Changed treatment regimen for subjects randomized to rezafungin treatment in Part B from Group 1 treatment to Group 2 treatment. Clarified that subjects are to complete the protocol version under which they enrolled. 2. Removed use of IVD except for preliminary screening at baseline. 3. Added requirement for 90-day period of contraception use by males. 4. Added Neuropathy and Tremors category of AEs of special interest. 5. Expanded infusion time up to 180 minutes if needed following an infusion reaction. 6. Clarified conditions and procedures for initial and repeated retinal examination. 7. Clarified that due to the staged start of Phase 3, which triggers rolling close of Part B, total enrollment depends on enrollment rate. 8. Replaced description of two formulations with description of a single formulation of lyophilized powder for reconstitution.